How Jevtana May Help

JEVTANA helped men live longer and also shrank tumors after docetaxel

JEVTANA was shown to be effective in 3 clinical studies with men who:

  • Had prostate cancer that spread to other parts of the body
  • Were no longer responding to medical or surgical treatment to lower testosterone
  • Had previously been treated with a chemotherapy called docetaxel

Results seen with JEVTANA

  • Study 1: Of the 755 men, 378 received JEVTANA and 377 received mitoxantrone
  • Study 2: Of the 255 men, 129 received JEVTANA and 126 received abiraterone or enzalutamide. Patients who had been previously treated with abiraterone or enzalutamide were treated with the alternate

Men Lived Longer

Study 1
15.1 months*
with JEVTANA
vs
12.7 months*
with mitoxantrone
Study 2
13.6 months*
with JEVTANA
vs
11.0 months*
with abiraterone or enzalutamide

3x More Men Had Tumors That Shrank

Study 1
14.4%
with JEVTANA
vs
4.4%
with mitoxantrone
Study 2
36.5%
with JEVTANA
vs
11.5%
with abiraterone or enzalutamide

Men Went Progression-free 2x Longer

Study 2
8.0 months*
with JEVTANA
vs
3.7 months*
with abiraterone or enzalutamide

*The number of months was measured using the “median.” In other words, half of the patients experienced numbers above the median and half of the patients experienced numbers below the median.

JEVTANA was shown to be safe and effective in Study 3, that looked at the risk and benefits of two different dosing options in 1200 men: 20 mg/m2 versus 25 mg/m2.

Please talk to your healthcare provider to learn more.

Did you know?

In Study 1, JEVTANA was compared to an active anticancer treatment called mitoxantrone. In Study 2, JEVTANA was compared to the hormone-based therapies abiraterone and enzalutamide.

These are different from a placebo-controlled study, where one treatment is compared with placebo–a substance or treatment with no active therapeutic effect.

CONSIDER JEVTANA SAFETY 
Understand Advanced Prostate Cancer 
SEE HOW JEVTANA IS GIVEN